Published today in Clinical Medicine Insights: Oncology is a new review article by Fuad El Rassi and Martha Arellano.  Read more about this paper below:

Title

Update on Optimal Management of Acute Myeloid Leukemia

Abstract

Acute myeloid leukemia (AML) represents a malignant accumulation of immature myeloid cells in the marrow, presenting with impaired hematopoiesis and its attendant complications, including bleeding, infection, and organ infiltration. Chromosomal abnormalities remain the most powerful predictors of AML prognosis and help to identify a subgroup with favorable prognosis. However, the majority of AML patients who are not in the favorable category succumb to the disease. Therefore, better efforts to identify those patients who may benefit from more aggressive and investigational therapeutic approaches are needed. Newer molecular markers aim at better characterizing the large group of intermediate-risk patients and to identify newer targets for therapy. A group that has seen little improvement over the years is the older AML group, usually defined as age ≥60. Efforts to develop less intensive but equally efficacious therapy for this vulnerable population are underway.

Click here to learn more about the article, download it and comment

share on